Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | MIR101-2 | Human | 1,3,5-trinitro-1,3,5-triazinane | increases expression | ISO | Mir101b (Mus musculus) | 6480464 | cyclonite results in increased expression of MIR101B mRNA | CTD | PMID:19270793 | MIR101-2 | Human | 2-hydroxypropanoic acid | increases expression | EXP | | 6480464 | Lactic Acid results in increased expression of MIR101-2 mRNA | CTD | PMID:30851411 | MIR101-2 | Human | 3-methylcholanthrene | multiple interactions | ISO | Mir101b (Mus musculus) | 6480464 | [Methylcholanthrene co-treated with Nanotubes, Carbon] results in increased expression of MIR101B mRNA | CTD | PMID:25926378 | MIR101-2 | Human | aflatoxin B1 | decreases expression | ISO | Mir101-2 (Rattus norvegicus) | 6480464 | Aflatoxin B1 results in decreased expression of MIR101B mRNA | CTD | PMID:24472605 | MIR101-2 | Human | atrazine | increases expression | ISO | Mir101-2 (Rattus norvegicus) | 6480464 | Atrazine results in increased expression of MIR101B mRNA | CTD | PMID:31185338 | MIR101-2 | Human | bis(2-ethylhexyl) phthalate | increases expression | ISO | Mir101b (Mus musculus) | 6480464 | Diethylhexyl Phthalate results in increased expression of MIR101B | CTD | PMID:32642447 | MIR101-2 | Human | bleomycin A2 | decreases expression | ISO | Mir101-2 (Rattus norvegicus) | 6480464 | Bleomycin results in decreased expression of MIR101B mRNA | CTD | PMID:25933445 | MIR101-2 | Human | bleomycin A2 | decreases expression | ISO | Mir101b (Mus musculus) | 6480464 | Bleomycin results in decreased expression of MIR101B mRNA | CTD | PMID:28726637 | MIR101-2 | Human | cadmium atom | multiple interactions | ISO | Mir101-2 (Rattus norvegicus) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MIR101-2 more ... | CTD | PMID:33652105 | MIR101-2 | Human | cadmium dichloride | multiple interactions | ISO | Mir101-2 (Rattus norvegicus) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MIR101-2 more ... | CTD | PMID:33652105 | MIR101-2 | Human | carbon nanotube | multiple interactions | ISO | Mir101b (Mus musculus) | 6480464 | [Methylcholanthrene co-treated with Nanotubes, Carbon] results in increased expression of MIR101B mRNA | CTD | PMID:25926378 | MIR101-2 | Human | choline | multiple interactions | ISO | Mir101b (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression more ... | CTD | PMID:20548288 | MIR101-2 | Human | folic acid | multiple interactions | ISO | Mir101b (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression more ... | CTD | PMID:20548288 | MIR101-2 | Human | furan | decreases expression | ISO | Mir101-2 (Rattus norvegicus) | 6480464 | furan results in decreased expression of MIR101B mRNA | CTD | PMID:22079235 | MIR101-2 | Human | L-methionine | multiple interactions | ISO | Mir101b (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression more ... | CTD | PMID:20548288 | MIR101-2 | Human | methimazole | multiple interactions | ISO | Mir101b (Mus musculus) | 6480464 | [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR101B mRNA | CTD | PMID:27421576 | MIR101-2 | Human | paracetamol | increases expression | ISO | Mir101-2 (Rattus norvegicus) | 6480464 | Acetaminophen results in increased expression of MIR101-2 mRNA | CTD | PMID:27397436 | MIR101-2 | Human | paracetamol | increases expression | ISO | Mir101b (Mus musculus) | 6480464 | Acetaminophen results in increased expression of MIR101B mRNA | CTD | PMID:19246379 | MIR101-2 | Human | paracetamol | affects expression | ISO | Mir101b (Mus musculus) | 6480464 | Acetaminophen affects the expression of MIR101B mRNA | CTD | PMID:19246379 | MIR101-2 | Human | rac-lactic acid | increases expression | EXP | | 6480464 | Lactic Acid results in increased expression of MIR101-2 mRNA | CTD | PMID:30851411 | MIR101-2 | Human | resveratrol | increases expression | ISO | Mir101b (Mus musculus) | 6480464 | Resveratrol results in increased expression of MIR101B mRNA | CTD | PMID:24817032 | MIR101-2 | Human | S-butyl-DL-homocysteine (S,R)-sulfoximine | multiple interactions | ISO | Mir101b (Mus musculus) | 6480464 | [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR101B mRNA | CTD | PMID:27421576 | MIR101-2 | Human | sodium arsenite | decreases expression | EXP | | 6480464 | sodium arsenite results in decreased expression of MIR101-2 mRNA | CTD | PMID:34032870 | MIR101-2 | Human | sodium fluoride | increases expression | ISO | Mir101b (Mus musculus) | 6480464 | Sodium Fluoride results in increased expression of MIR101B mRNA | CTD | PMID:29127033 | MIR101-2 | Human | sodium fluoride | increases expression | ISO | Mir101-2 (Rattus norvegicus) | 6480464 | Sodium Fluoride results in increased expression of MIR101B | CTD | PMID:37121298 | MIR101-2 | Human | streptozocin | increases expression | ISO | Mir101b (Mus musculus) | 6480464 | Streptozocin results in increased expression of MIR101B mRNA | CTD | PMID:27629361 | MIR101-2 | Human | tetrachloromethane | increases expression | ISO | Mir101-2 (Rattus norvegicus) | 6480464 | Carbon Tetrachloride results in increased expression of MIR101-2 mRNA | CTD | PMID:27397436 | MIR101-2 | Human | zinc atom | increases expression | ISO | Mir101-2 (Rattus norvegicus) | 6480464 | Zinc deficiency results in increased expression of MIR101B mRNA | CTD | PMID:22689922 | MIR101-2 | Human | zinc(0) | increases expression | ISO | Mir101-2 (Rattus norvegicus) | 6480464 | Zinc deficiency results in increased expression of MIR101B mRNA | CTD | PMID:22689922 | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





















